While the quarter was solid and 2026 is shaping up to be better than 2025, the progress has been slower than we would like.
Get this delivered to your inbox, and more info about our products and services.
Danaher's rebound is generating optimism, but there's still work ahead for the company to hit is 2026 growth targets.
The supplier of tools to drugmakers and hospitals is set up for a stronger 2026.
Danaher shares fell on the news that it was acquiring medtech player Masimo.
Shares of this company tumbled Tuesday after the CFO said some disappointing things about the U.S. business.
Shares have tumbled over 60% from their November 2024 highs driven by fundamentals but also marked by an unthinkable shock.
The company's earnings report wasn't perfect, but the long-term story is still intact.
